SCHEMBL910448

SCHEMBL910448

CCCc1ccccc1[C]=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 1/20 0.38
GABRA1 P14867 3/20 0.36
GABRB2 P47870 3/20 0.36
HTR1A P08908 1/20 0.36
FFAR1 O14842 1/20 0.35
CYP2D6 P10635 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP2E1 P05181 1/20 0.34
CYP2C8 P10632 1/20 0.34
CYP2A6 P11509 1/20 0.34
CYP2B6 P20813 1/20 0.34
LIPG Q9Y5X9 1/20 0.33
AR P10275 1/20 0.33
PPARG P37231 1/20 0.33
PPARA Q07869 1/20 0.33
ADRA2A P08913 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
RAB9A P51151 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2119420 0.88 CYP3A4 (0.44) CYP2D6CYP2C9CYP2C19LIPGPPARG
SCHEMBL1584216 0.86 LIPG (0.50) LIPGPPARGPPARA
SCHEMBL10708843 0.84 LIPG (0.53) LIPGPPARGPPARA
SCHEMBL2121348 0.84 LIPG (0.53) LIPGPPARGPPARA
SCHEMBL10473131 0.84 LIPG (0.53) LIPGPPARGPPARA
SCHEMBL6222240 0.84 LIPG (0.53) LIPGPPARGPPARA
SCHEMBL2119800 0.84 LIPG (0.53) LIPGPPARGPPARA
SCHEMBL535892 0.84 GABRA1 (0.45) GABRA1GABRB2FFAR1CYP2D6MAPT
SCHEMBL1141480 0.82 HTR1A (0.38) DAOGABRA1GABRB2HTR1AFFAR1
SCHEMBL9744164 0.78 TDP1 (0.39) FFAR1CYP1A2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114681473-A Application of glucosamine and derivatives thereof as anti-novel coronavirus drugs 南湖实验室 2022-07-01 CN claimed
CN-112336733-A Application of glucosamine and derivatives thereof as anti-novel coronavirus drugs 南湖实验室 2021-02-09 CN claimed
EP-1937622-A1 COMPOUNDS FOR TREATMENT OF LIPASE-MEDIATED DISEASES Reliance Life Sciences Pvt., Ltd. (IN) 2008-07-02 EP claimed
US-20070054958-A1 Compounds for treatment of lipase-mediated diseases RELIANCE LIFE SCIENCES PVT. LTD. (IN) 2007-03-08 US claimed
WO-2007010546-A1 COMPOUNDS FOR TREATMENT OF LIPASE-MEDIATED DISEASES RELIANCE LIFE SCIENCES PVT LTD (IN) 2007-01-25 WO claimed
EP-0599819-B1 Use of hydroxycarboxylic acids and derivatives for the preparation of topical dermatologic compositions for the treatment of wrinkles SCOTT EUGENE J VAN (US) 1997-04-02 EP claimed
US-4994468-A Bronchodilators, antiallergens KYOWA HAKKO KOGYO CO., LTD. (JP) 1991-02-19 US claimed
CN-117860712-A Ammonia sugar composition for inhalation, preparation method and application thereof 中国人民解放军军事科学院军事医学研究院 2024-04-12 CN disclosed
WO-2024024760-A1 PYRAZOLONE COMPOUND AND PYRAZOLONE AGENT 公益財団法人野口研究所 2024-02-01 WO disclosed
CN-114732822-A Application of glucosamine and derivatives thereof as antiviral drugs 中国人民解放军军事科学院军事医学研究院 2022-07-12 CN disclosed
CN-114732823-A Application of glucosamine and derivatives thereof as antiviral drugs 中国人民解放军军事科学院军事医学研究院 2022-07-12 CN disclosed
CN-114681473-A Application of glucosamine and derivatives thereof as anti-novel coronavirus drugs 南湖实验室 2022-07-01 CN disclosed
CN-114681472-A Application of glucosamine and derivatives thereof as antiviral drugs 中国人民解放军军事科学院军事医学研究院 2022-07-01 CN disclosed
EP-0386722-A1 Imidazoquinolone derivatives KYOWA HAKKO KOGYO CO., LTD. (JP) 1990-09-12 EP disclosed
EP-0330241-A2 Calcitonin derivatives OTSUKA PHARMACEUTICAL CO., LTD. (JP) 1989-08-30 EP disclosed
US-4753951-A ANTIDEPRESSANTS, ANXIOLYTICS SHIONOGI & CO., LTD. (JP) 1988-06-28 US disclosed
EP-0223420-A1 Condensed imidazopyridine derivatives SHIONOGI & CO., LTD. (JP) 1987-05-27 EP disclosed
US-4438277-A Hydronaphthalene derivatives SANKYO COMPANY, LIMITED (JP) 1984-03-20 US disclosed
US-4361515-A Antihyperlipemic dihydro-ML-236B derivatives, their preparation and use SANKYO COMPANY, LIMITED (JP) 1982-11-30 US disclosed
US-4255151-A ANTHRAQUINONE DYES, SWELLING, HEAT FIXING BAYER AKTIENGESELLSCHAFT (DE) 1981-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070054958-A1 Compounds for treatment of lipase-mediated diseases LIPE, LIPG, LPL DAO 1175/4885GABRA1 4257/4885GABRB2 3956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.